Clinical trials: Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Condition Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Funder type Industry (pharma, biotech, devices)
Advanced Non-small Cell Lung Cancer, Cancer
Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation
The purpose of this Expanded Access Program (EAP) is to provide access to sevabertinib, for participants previously treated with locally advanced or metastatic non-small cell lung cancer (NSCLC) with mutations in the human…
- Trial name
- NCT06761976
- Testing
- Sevabertinib
- Sponsor
- Bayer
Non-small-cell Lung Cancer
Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
The primary purpose of this research study is to see whether adding bavituximab (an investigational drug) to the standard chemotherapy drug docetaxel, will improve the results of the treatment for non-small-cell lung cancer.
- Trial name
- NCT01138163
- Where
- 53 sites in United States, Georgia and 3 more
- Volunteers
- 121 people
- Sponsor
- Peregrine Pharmaceuticals
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer
This study is a Phase Ib, open label, multi-center study of to evaluate the safety and efficacy of JMT101 combined with EGFR-TKIs (Afatinib or Osimertinib) in patients with locally advanced or metastatic non-small cell lung…
- Trial name
- NCT04448379
- Testing
- JMT101
- Where
- 13 sites in China
- Volunteers
- 48 people
- Sponsor
- Shanghai JMT-Bio Inc.
Carcinoma, Non-Small-Cell Lung
Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer)
This is an observational cohort study of patients with locally advanced or metastatic NSCLC (non-small cell lung cancer). Patients will be recruited from participating sites in Europe, Asia, and Canada.
- Trial name
- PANORAMA (NCT03053297)
- Testing
- Patient Reported Outcomes
- Where
- 110 sites in Canada, China and 4 more
- Volunteers
- 89 people
- Sponsor
- AstraZeneca
Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
A multicenter, single-arm, first-in-human study to investigate the safety, pharmacokinetics, and preliminary antitumor activity of PLX-61639 in participants with locally advanced or metastatic, relapsed/refractory…
- Conditions
- Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- NCT07284186
- Testing
- PLX-61639
- Where
- 10 sites in United States
- Volunteers
- 155 people
- Sponsor
- Plexium, Inc.
Lung Cancer
Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment
the primary objective is to characterise the impact of gefitinib on the Response Evaluation Criteria in Solid Tumours (RECIST) based assessments; objective response rate (ORR ; confirmed complete response(CR) or partial response…
- Trial name
- ICARUS (NCT01530334)
- Testing
- Gefitinib 250mg
- Where
- 24 sites in Italy
- Volunteers
- 61 people
- Sponsor
- AstraZeneca
Cancer, Solid Tumor
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
This study will evaluate safety, pharmacodynamics and biomarkers of subcutaneous (SC) DK210(EGFR) given as monotherapy and in combination with immunotherapy, chemotherapy or radiation.
- Conditions
- Cancer, Solid Tumor, Colorectal Cancer, Pancreas Cancer
- Trial name
- NCT05704985
- Testing
- DK210 (EGFR), Radiation therapy, Immune checkpoint blockers
- Where
- 7 sites in United States
- Volunteers
- 39 people
- Sponsor
- DEKA Biosciences
Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets (ABK3376 Tablets) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
This study is a multicenter, single arm, open label, phase I clinical trial, including dose escalation (phase IA) and dose expansion (phase IB).
- Trial name
- NCT06955988
- Testing
- AST2303 Tablets(ABK3376 Tablets) ，25mg, AST2303 Tablets(ABK3376 Tablets) ，50mg, AST2303 Tablets(ABK3376 Tablets) ，75mg
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Allist Pharmaceuticals, Inc.
Non-Small Cell Lung Cancer
Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET
MGCD265 is an orally administered receptor tyrosine kinase inhibitor that targets MET and other receptors. This study is a Phase 2 trial of MGCD265 in patients with locally advanced, unresectable or metastatic non-small cell lung…
- Trial name
- NCT02544633
- Testing
- MGCD265
- Where
- 94 sites in United States, Australia and 7 more
- Volunteers
- 68 people
- Sponsor
- Mirati Therapeutics Inc.
Non-Small Cell Lung Cancer
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
This is a Phase II, multi-center, open-label platform study evaluating novel combination treatment options in participants with locally advanced or metastatic NSCLC.
- Trial name
- LIBRA (NCT07098338)
- Testing
- Rilvegostomig, Ramucirumab, Dato-DXd
- Where
- 83 sites in United States, Australia and 10 more
- Volunteers
- 278 people
- Sponsor
- AstraZeneca
NSCLC (Advanced Non-small Cell Lung Cancer), Colorectal Cancer
Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors
This is a prospective, open-label, exploratory clinical study to evaluate the safety and preliminary efficacy of allogeneic natural killer (NK) cell injection combined with standard maintenance therapy in patients with locally…
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), Colorectal Cancer, Advanced Solid Tumors, Advanced Hepatocellular Carcinoma (HCC)
- Trial name
- NCT07551778
- Testing
- NK Cells, NK cells + PD-(L)1 inhibitor + pemetrexed as first-line maintenance therapy, NK cells + cetuximab/bevacizumab + capecitabine as first-line maintenance therapy
- Volunteers
- 42 people
- Sponsor
- BOE Technology Group Co., Ltd.
Non Small Cell Lung Cancer
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
This is a Phase II, Open Label, Multicenter, Single Arm Study of WSD0922-FU for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with First-Line Osimertinib Treatment and whose…
- Trial name
- NCT06868485
- Testing
- WSD0922-FU Tablets, Dose level A, WSD0922-FU Tablets, Dose level B
- Where
- 18 sites in United States, China and 1 more
- Volunteers
- 40 people
- Sponsor
- Wayshine Biopharm, Inc.
Non-small Cell Lung Cancer
Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)
This is a multi-center, open-label, randomized, Phase 1b/2 study to determine the recommended phase 2 dose (RP2D) and to evaluate the efficacy in terms of progression free survival (PFS) of Tepotinib when used in combination with…
- Trial name
- NCT01982955
- Testing
- Tepotinib, Gefitinib, Pemetrexed
- Where
- 44 sites in China, Italy and 5 more
- Volunteers
- 88 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Non Small Cell Lung Cancer
A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer
The purpose of this study is to compare two different approaches to treating non-small cell lung cancer (NSCLC) in East Asian never-smoker participants.
- Trial name
- NCT01017874
- Testing
- Pemetrexed, Cisplatin, Gefitinib
- Where
- 12 sites in Hong Kong, Singapore and 3 more
- Volunteers
- 236 people
- Sponsor
- Eli Lilly and Company
Non-Squamous Non-Small Cell Lung Cancer
Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure
The anti-tumor activity of anti-PD-1 therapy and VEGF inhibitor in TKI-resistant EGFR-mutated non-squamous NSCLC Chinese patients will be investigated in this clinical trial.
- Trial name
- NCT03802240
- Testing
- Sintilimab, IBI305, Pemetrexed
- Where
- China
- Volunteers
- 492 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Advance Solid Tumors
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.
- Trial name
- NCT07229313
- Testing
- KIVU-107
- Where
- 7 sites in United States, Australia
- Volunteers
- 76 people
- Sponsor
- Kivu Bioscience Inc.
Carcinoma
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
This study (the SAVANNAH study) will investigate the efficacy of osimertinib in combination with savolitinib in participants with epidermal growth factor receptor mutation positive (EGFRm+) and mesenchymal epithelial transition…
- Trial name
- SAVANNAH (NCT03778229)
- Testing
- Osimertinib, Savolitinib
- Where
- 90 sites in United States, Brazil and 11 more
- Volunteers
- 367 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer, Solid Tumor
A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
This study is an open-label, multicenter, dose-escalation and cohort-expansion, non-randomized Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M09D1 for…
- Trial name
- NCT07056556
- Testing
- BL-M09D1
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Imaging, Colorectal Cancer
A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.
LNTH-2403 (177Lu-DOTA-DUNP19) is a lutetium-177 radiolabeled, fully humanized monoclonal antibody (mAb) that binds with high specificity and affinity to leucine-rich repeat containing 15 (LRRC15), a transforming growth factor…
- Conditions
- Imaging, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer
- Trial name
- DUNP19 (NCT07272642)
- Testing
- LNTH-2403
- Where
- Australia
- Volunteers
- 16 people
- Sponsor
- Radiopharm Theranostics, Ltd
Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
The purpose of this study is to evaluate the safety and efficacy of zipalertinib in combination with standard first-line platinum-based chemotherapy compared to chemotherapy alone, in patients with locally advanced or metastatic…
- Trial name
- REZILIENT3 (NCT05973773)
- Testing
- TAS6417
- Where
- 110 sites in United States, Belgium and 20 more
- Volunteers
- 285 people
- Sponsor
- Taiho Oncology, Inc.